Should Antibiotics Be Controlled Medicines? Lessons from the Controlled Drug Regimen

Abstract

This study aimed to identify the antibiotic-relevant lessons from the controlled drug regimen for narcotics. Whereas several elements of the United Nations Single Convention on Narcotic Drugs (1961) could be advantageous for antibiotics, we doubt that an international legally binding agreement for controlling antibiotic consumption would be any more effective than implementing stewardship measures through national AMR plans.

Get full access to this article

View all access options for this article.

References

C. L.

Ventola

, “The Antibiotic Resistance Crisis: Part 1: Causes and Threats,” Pharmacy and Therapeutics 40, no. 4 (2015): 277-283.

World Health Organization, Antimicrobial Resistance: Global Report on Surveillance, available at <http://www.who.int/drugresistance/documents/surveillancereport/en/> (last visited April 2, 2018).

B. G.

Bell

et al ., “A Systematic Review and Meta-analysis of the Effects of Antibiotic Consumption on Antibiotic Resistance,” BMC Infectious Diseases 14, no. (2014): 13.

K. E.

Fleming-Dutra

et al ., “Prevalence of Inappropriate Antibiotic Prescriptions among US Ambulatory Care Visits, 2010-2011,” JAMA 315, no. 17 (2016): 1864-1873.

Mendelson

et al ., “Maximising Access to Achieve Appropriate Human Antimicrobial Use in Low-Income and Middle-Income Countries,” The Lancet 387, no. 10014 (2016): 188-198.

Daulaire

et al ., “Universal Access to Effective Antibiotics Is Essential for Tackling Antibiotic Resistance,” Journal of Law, Medicine & Ethics 43, Suppl. 3, no. (2015): 17-21.

S. J.

Hoffman

et al ., “An International Legal Framework to Address Antimicrobial Resistance,” Bulletin of the World Health Organization 93, no. 2 (2015): 66; C. Årdal et al., “International Cooperation to Improve Access to and Sustain Effectiveness of Antimicrobials,” The Lancet 387, no. 10015 (2016): 296-307.

United Nations Treaty Collection, Status of Treaties: Chapter VI Narcotic Drugs and Psychotropic Substances, available at <https://treaties.un.org/pages/viewdetails.aspx?src=treaty&mtdsg_no=vi-18&chapter=6&lang=en> (last visited April 2, 2018).

United Nations. Single Convention on Narcotic Drugs (1961).

10.

International Narcotics Control Board, Training Material: 1961 Single Convention on Narcotic Drugs. Part 1: The International Control System for Narcotic Drugs (2005), available at <https://www.incb.org/documents/Narcotic-Drugs/Training-Materials/English/PART_I_English.pdf> (last visited April 2, 2018).

11.

Jelsma

, The Development of International Drug Control. Lessons Learned and Strategic Challenges for the Future: Series on Legislative Reform of Drug Policies, No. 10 (March 2011), available at <https://www.tni.org/files/download/dlr10.pdf>.

12.

World Health Organization, Access to Controlled Medications Programme. Improving access to medications controlled under international drug conventions. Briefing note., available at <http://www.who.int/medicines/areas/quality_safety/ACMP_BrNote_Genrl_EN_Apr2012.pdf> (last visited 1 July 2016).

13.

O'Brien

et al ., “Improving Access to Analgesic Drugs for Patients with Cancer in Sub-Saharan Africa,” The Lancet Oncology 14, no. 4 (2013): e176-182.

14.

Larance

et al ., “The Availability, Diversion and Injection of Pharmaceutical Opioids in South Asia,” Drug and Alcohol Review 30, no. 3 (2011): 246-254.

15.

Berterame

et al ., “Use of and Barriers to Access to Opioid Analgesics: A Worldwide, Regional, and National Study,” The Lancet 387, no. 10028 (2016): 1644-1656.

16.

S. A.

Husain

et al ., “Do National Drug Control Laws Ensure the Availability of Opioids for Medical and Scientific Purposes?” Bulletin of the World Health Organization 92, no. 2 (2014): 108-116.

17.

See Berterame et al., supra note 15.

18.

Degenhardt

et al ., “The Global Epidemiology and Burden of Opioid Dependence: Results from the Global Burden of Disease 2010 Study,” Addiction 109, no. 8 (2014): 1320-1333.

19.

Kolodny

et al ., “The Prescription Opioid and Heroin Crisis: A Public Health Approach to an Epidemic of Addiction,” Annual Review of Public Health 36 (2015): 559-574.

20.

J. M.

Tetrault and

J. L.

Butner , “Non-Medical Prescription Opioid Use and Prescription Opioid Use Disorder: A Review,” Yale Journal of Biology and Medicine 88, no. 3 (2015): 227-233.

21.

Csete

et al ., “Public Health and International Drug Policy,” The Lancet 387, no. 10026 (2016): 1427-1480.

22.

See United Nations, supra note 9.

23.

World Health Organization, WHO List of Critically Important Antimicrobials (CIA), available at <http://www.who.int/foodsafety/areas_work/antimicrobial-resistance/cia/en/> (last visited April 2, 2018).

24.

World Health Organization, WHO Model Lists of Essential Medicines, available at <http://www.who.int/medicines/publications/essentialmedicines/en/> (last visited April 2, 2018).

25.

Manchikanti

et al ., “Current State of Opioid Therapy and Abuse,” Current Pain and Headache Reports 20, no. 5 (2016): 1-9.

26.

Linge-Dahl

et al ., “Identification of Challenges to the Availability and Accessibility of Opioids in Twelve European Countries: Conclusions from Two ATOME Six-Country Workshops,” Journal of Palliative Medicine 18, no. 12 (2015): 1033-1039.

27.

N. I.

Cherny

et al ., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer Pain in Europe: A Report from the ESMO/EAPC Opioid Policy Initiative,” Annals of Oncology 21, no. 3 (2010): 615-626.

28.

Cleary

et al ., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer Pain in India: A Report from the Global Opioid Policy Initiative (GOPI),” Annals of Oncology 24, Suppl. 11, no. (2013): xi33-xi40.

29.

M. R.

Rajagopal and

D. E.

Joranson , “India: Opioid Availability. An Update,” Journal of Pain and Symptom Management 33, no. 5 (2007): 615-622.

30.

G. P.

Dureja

et al ., “Addressing the Barriers Related with Opioid Therapy for Management of Chronic Pain in India,” Pain Management 7, no. 4 (2017): 311-330.

31.

Helseog omsorgsdepartementet, Handlingsplan mot anti-biotikaresistens i helsetjenesten, available at <https://www.regjeringen.no/contentassets/915655269bc04a47928fce917e4b25f5/handlingsplan-antibiotikaresistens.pdf> (last visited April 2, 2018).

32.

D. J.

Morgan

et al ., “Non-prescription Antimicrobial Use Worldwide: A Systematic Review,” The Lancet Infectious Diseases 11, no. 9 (2011): 692-701.

33.

Ocan

et al ., “Household Antimicrobial Self-Medication: A Systematic Review and Meta-analysis of the Burden, Risk Factors and Outcomes in Developing Countries,” BMC Public Health 15 (2015): 742.

34.

A. G.

Mainous, 3rd, et al., “Availability of Antibiotics for Purchase without a Prescription on the Internet,” The Annals of Family Medicine 7, no. 5 (2009): 431-435.

35.

World Health Organization, Antimicrobial Resistance. National Action Plans, available at <http://www.who.int/antimicrobial-resistance/national-action-plans/en/> (last visited April 2, 2018).

36.

Blue Cross Blue Shield, The Health of America Report. Antibiotic Prescription Fill Rates Declining in the U.S. (2017), available at <https://www.bcbs.com/sites/default/files/file-attachments/health-of-america-report/HoA.Antibiotics.Report.pdf> (last visited April 2, 2018).

37.

United Nations: International Narcotics Control Board, Report of the International Narcotics Control Board for 2015 (January 2016), available at <https://www.incb.org/documents/Publications/AnnualReports/AR2015/English/AR_2015_E.pdf> (last visited April 2, 2018).

38.

Dalal and

Bruera , “Access to Opioid Analgesics and Pain Relief for Patients with Cancer,” Nature Review Clinical Oncology 10, no. 2 (2013): 108-116.

39.

See O'Brien et al., supra note 13.

40.

International Narcotics Control Board, Guide on Estimating Requirements for Substances under International Control. Developed by the International Narcotics Control Board and the World Health Organization for Use by Competent National Authorities (2012), available at <https://www.incb.org/documents/Narcotic-Drugs/Guidelines/estimating_requirements/NAR_Guide_on_Estimating_EN_Ebook.pdf> (last visited April 2, 2018).

41.

World Health Organization, WHO Methodology for a Global Programme on Surveillance of Antimicrobial Consumption, available at <http://www.who.int/medicines/areas/rational_use/WHO_AMCsurveillance_1.0.pdf> (last visited April 2, 2018).

42.

European Centre for Disease Prevention and Control, European Surveillance of Antimicrobial Consumption Network (ESAC-Net), available at <https://ecdc.europa.eu/en/about-us/partnerships-and-networks/disease-and-laboratory-networks/esac-net-about> (last visited April 2, 2018).

43.

Wellcome Trust, Fleming Fund Launched to Tackle Global Problem of Drug-Resistant Infection, available at <https://wellcome.ac.uk/press-release/fleming-fund-launched-tackle-global-problem-drug-resistant-infection> (last visited April 2, 2018).

44.

Cleary

et al ., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer Pain in Africa: A Report from the Global Opioid Policy Initiative (GOPI),” Annals of Oncology 24, no. 11 Supp (2013): xi14-xi23; J. Cleary et al., “Formulary Availability and Regulatory Barriers to Accessibility of Opioids for Cancer Pain in Asia: A Report from the Global Opioid Policy Initiative (GOPI),” Annals of Oncology 24, no. 11 Supp (2013): xi24-xi32.

45.

See Cherny et al., supra note 27.

46.

The Review on Antimicrobial Resistance, Chaired by

Jim

O'Neill

, Antimicrobials in Agriculture and the Environment: Reducing Unnecessary Use and Waste (December 2015), available at <https://amr-review.org/sites/default/files/Antimicrobials%20in%20agriculture%20and%20the%20environment%20-%20Reducing%20unnecessary%20use%20and%20waste.pdf> (last visited April 2, 2018).

47.

See World Health Organization, supra note 35.

48.

United Nations, Political Declaration of the High-Level Meeting of the General Assembly on Antimicrobial Resistance (2016), available at <http://www.un.org/pga/71/wp-content/uploads/sites/40/2016/09/DGACM_GAEAD_ESCAB-AMR-Draft-Political-Declaration-1616108E.pdf> (last visited April 2, 2018).

49.

G20 Germany 2017, Berlin Declaration of the G20 Health Ministers, available at <https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/G/G20-Gesundheitsministertreffen/G20_Health_Ministers_Declaration_engl.pdf> (last visited April 2, 2018).